A PHASE-1, OPEN-LABEL, SINGLE-DOSE STUDY OF THE PHARMACOKINETICS OF BUPARLISIB IN SUBJECTS WITH MILD TO SEVERE HEPATIC IMPAIRMENT ArticleCsonka D., Hazell K., Waldron E., Lorenzo S., Duval V., Trandafir L., Kobalava Z.D.Journal of Clinical Pharmacology. Том 56. 2016. С. 316-323